Literature DB >> 2897451

The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride.

W L Smith1, E M Callaham, R S Alphin.   

Abstract

Cisplatin administered by either the intravenous (i.v.) or intra-cerebroventricular (i.c.v.) route produced emesis in cats. The average time to onset of emesis was decreased significantly (4.0 min versus 100.6 min) when cisplatin was administered i.c.v. Zacopride administered either i.c.v. (0.02 mg) or i.v. (0.1 mg kg-1) completely blocked the emesis due to cisplatin given by either route. Their data show that cisplatin possesses a central emetic component and that this is blocked by zacopride.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897451     DOI: 10.1111/j.2042-7158.1988.tb05202.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  13 in total

Review 1.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Topographical distribution of 5-HT3 receptor recognition sites in the ferret brain stem.

Authors:  J M Barnes; N M Barnes; B Costall; I L Naylor; R J Naylor; J A Rudd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

Review 3.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Cisplatin-induced early and delayed emesis in the pigeon.

Authors:  S Tanihata; H Igarashi; M Suzuki; T Uchiyama
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 5.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

6.  Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors.

Authors:  Neema K Pithia; Christopher Liang; Xiang-Zuo Pan; Min-Liang Pan; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2016-03-08       Impact factor: 2.823

7.  5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.

Authors:  G A Higgins; G J Kilpatrick; K T Bunce; B J Jones; M B Tyers
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

8.  Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).

Authors:  Bart C De Jonghe; Charles C Horn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

9.  Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.

Authors:  J Herrstedt; J Hyttel; J Pedersen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  In vitro release and tissue levels of ileal serotonin after cisplatin-induced emesis in the cat.

Authors:  S Milano; C Simon; L Grélot
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.